In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finding the Opportunities in Aptamers

Executive Summary

The world is waking up to aptamers. With a few big deals and a small flock of products in the clinic, aptamers' boosters see the molecules largely replacing antibodies; they've got many of the advantages of both large and small molecules, plus the added advantage of speedy creation. But they still face major technological challenges-including high manufacturing costs, limited half-lives, and problems with intracellular targets. The three players whose strategies we profile here-Corgentech, Coley and Archemix--have all chosen to pursue opportunities with aptamers which avoid their biggest problems. But the solutions also limit these companies' abilities to fully exploit the aptamer platform.
Advertisement

Related Content

Archemix Reduces Aperture to Pursue Orphan Diseases
Archemix Reduces Aperture to Pursue Orphan Diseases
Reviewing 2005: The Top Biopharma Stories
Aptamers: Two Deals Down, One Big Deal Up
Afmedica Inc.
Technology Investing: One VC's View of the Value Proposition for Today's Market
Angiotech: Specialty Pharma in the Device World
Bioteching UCB-and Maybe Mid-Sized Pharma, Too
RNAi Firms Unite Rather than Fight
Gilead's Metamorphoses

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel